NCT02023918View on ClinicalTrials.gov

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
DiabetesMetabolic SyndromeInsulin Resistance
Interventions
DRUG

pegvisomant

Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

All Listed Sponsors
collaborator

San Francisco General Hospital

OTHER

lead

University of California, San Francisco

OTHER

NCT02023918 - Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes | Biotech Hunter | Biotech Hunter